« Back
Home /
Enavogliflozin

Enavogliflozin

Item no.	HY-109144-5mg
Manufacturer	MedChem Express
CASRN	1415472-28-4
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	98.43
Citations	[1]Daewoong speeds up developing antidiabetic Enavogliflozin\|[2]These are the results of clinical trials of the diabetes drug Enavogliflozin and Metformin\|[3]Global Diabetes Pipeline Landscape Report 2020 Featuring Daewoong's Enavogliflozin & Janssen Biotech's Golimumab Among Others - ResearchAndMarkets.com
Smiles	O[C@H]([C@H]1O)[C@@H](O[C@H](CO)[C@H]1O)C2=C(CCO3)C3=C(Cl)C(CC4=CC=C(C5CC5)C=C4)=C2
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	DWP-16001
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	SGLT
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	446.92
Product Description	Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor[1][2][3].
Manufacturer - Research Area	Metabolic Disease
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Membrane Transporter/Ion Channel
Isoform	SGLT2
Clinical information	Phase 4

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-109144-5mg-safety-datasheet.pdf